ClinicalTrials.gg
CompletedNCT00479336Updated Mar 14, 2014Results posted

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

A Phase 2 interventional study of OPC-41061 7.5mg and OPC-41061 placebo in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-14.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

To investigate the dose response for changes from baseline in body weight as a primary endpoint and to investigate improvement in ascites, abdominal circumference, lower-limb edema, and pleural effusion as secondary endpoints in seven-day repeated oral administration of OPC-41061 at 7.5, 15, and 30 mg/day or placebo in cirrhosis patients with ascites despite taking conventional diuretics.

02

Conditions studied

  • Cirrhosis

Browse trials for

Keywords

  • OPC-41061
  • Tolvaptan
  • ascites
  • Cirrhosis
03

In context

Fibrosis Unverified

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

This study's enrollment of 104 is above the median of 63 across 841 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with ascites despite taking either of the following combinations of loop diuretics and an anti-aldosterone agent (spironolactone) for at least 7 days prior to start of the study drug administration.

    Combination 1: Loop diuretics at indicated below in combination with an anti-aldosterone agent at a daily dose of 25 mg or more

    • Furosemide: 40 mg/day or more
    • Other loop diuretic: a daily dosage equivalent to 40 mg or more of furosemide Bumetanide: 1 mg/day or more, Piretanide: 6 mg/day or more, Azosemide: 60 mg/day or more, Torasemide: 8 mg/day or more Combination 2: Anti-aldosterone agent at a daily dose of 50 mg or more in combination with furosemide at a daily dose of 20 mg or more (or one of the other loop diuretics specified in Combination 1 at a daily dosage equivalent to 20 mg or more of furosemide)
  2. Patients who have been hospitalized or are able to stay at the study site from the start of the run-in observation period until completion of postdosing observation 2.
  3. Subjects capable of giving to participate in the study of their own free will.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any of the following complications or symptoms: (1) Hepatic encephalopathy (Hepatic coma grade: II or more), (2) Poorly-controlled hepatocellular carcinoma (i.e., hepatocellular carcinoma with vessel infiltration confirmed by imaging in the main trunk or main branch of the portal vein, inferior vena cava, or the main trunk of the hepatic vein), (3)Endoscopic findings within 30 days prior to screening examination requiring new therapy for esophageal and gastric varicose vein during the study period, (4)Repeated haemorrhoidal bleeding due to rectal varicose vein within 30 days prior to screening examination, (5)Diabetes mellitus with poorly controlled blood glucose, (6)Heart failure ( class III or IV), (7)Anuria, (8)Impairment of urination due to urinary tract stricture, urinary calculus, tumor in the urinary tract, or other cause
  2. Subjects with a history of any of the following diseases: (1) Cerebrovascular disorder within 30 days prior to the screening examination, (2)Episode of gout within 90 days prior to the screening examination, (3) or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
  3. Subjects who are obese ( [BMI, body weight (kg)/height (m)2] exceeding 35)
  4. Patients with supine systolic blood pressure exceeding 90 mmHg
  5. Subjects with any of following abnormal laboratory values: exceeding 8.0 g/dL, total exceeding 3.0 mg/dL, serum creatinine exceeding 3.0 mg/dL, serum sodium exceeding 147 mEq/L, serum potassium exceeding 5.5 mEq/L, or uric acid exceeding 8.0 mg/dL
  6. Patients who are unable to take oral medication
  7. Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant
  8. Subjects who received blood products, including albumins, within 7 days prior to the screening examination
  9. Subjects who received any drug other than OPC-41061 within 30 days prior to the screening examination
  10. Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061
  11. Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Placebo comparator
    1

    Drug: OPC-41061 placebo

  • Experimental
    2

    Drug: OPC-41061 7.5mg

  • Experimental
    3

    Drug: OPC-41061 15mg

  • Experimental
    4

    Drug: OPC-41601 30mg

Interventions

  • 7.5mg, 1 tablet a day

  • DrugOPC-41061 placebo

    placebo, 1 tablet a day

  • 15mg, 1 tablet a day

  • DrugOPC-41601 30mg

    30mg, 1 tablet a day

06

What researchers measure

Primary outcomes

  1. Body Weight (Amount of Change)

    Changes in body wight from baseline at the final timepoint (LOCF). A linear regression model using changes in body weight from baseline at the final timepoint as the criterion variable and dose as the explanatory variable was fitted to the dataset.

    Time frame: Baseline, Day 7 or at the discontied of treatment

Secondary outcomes

  1. Abdominal Circumference

    Change in abdominal circumference from baseline (LOCF)

    Time frame: Baseline, Day 7 or at the discontied of treatment

07

Results

Posted Mar 14, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Started27262526
Completed23202421
Not completed4615
Withdrew: Adverse event1113
Withdrew: Lack of efficacy1000
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject1200
Withdrew: Physician decision0102
Withdrew: Resolution of all hepatic edema findings1100

Outcome measures

PrimaryBody Weight (Amount of Change)

Changes in body wight from baseline at the final timepoint (LOCF). A linear regression model using changes in body weight from baseline at the final timepoint as the criterion variable and dose as the explanatory variable was fitted to the dataset.

Time frame:
Baseline, Day 7 or at the discontied of treatment
Reported as:
Mean · Kg
Body Weight (Amount of Change)
KgPlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Body Weight (Amount of Change)-0.68 ± 2.50-2.31 ± 2.35-1.88 ± 2.45-1.67 ± 1.46
Statistical analysis
  • Placebo vs OPC-41061 7.5 mg vs OPC-41061 15 mg vs OPC-41061 30 mg · Regression, Linear · p = 0.3167 · Slope: -0.021 · 95% CI -0.061 to 0.020
SecondaryAbdominal Circumference

Change in abdominal circumference from baseline (LOCF)

Time frame:
Baseline, Day 7 or at the discontied of treatment
Reported as:
Mean · cm
Abdominal Circumference
cmPlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Abdominal Circumference-1.39 ± 3.16-2.98 ± 3.22-2.42 ± 3.96-2.62 ± 2.83

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/26 (19.2%)18/26 (69.2%)
OPC-41061 7.5 mg—0/25 (0%)20/25 (80%)
OPC-41061 15 mg—1/25 (4%)19/25 (76%)
OPC-41061 30 mg—3/25 (12%)24/25 (96%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
Gastrointestinal HaemorrhageGastrointestinal disorders0/260/250/251/25
Hepatic FailureHepatobiliary disorders1/260/250/251/25
Hepatic EncephalopathyNervous system disorders0/260/250/251/25
Renal ImpairmentRenal and urinary disorders0/260/251/250/25
Shock HaemorrhagicVascular disorders0/260/251/250/25
AnaemiaBlood and lymphatic system disorders1/260/250/250/25
Abdominal DistensionGastrointestinal disorders1/260/250/250/25
Chronic HepatitisHepatobiliary disorders1/260/250/250/25
Hepatorenal SyndromeHepatobiliary disorders1/260/250/250/25
Hepatitis BInfections and infestations1/260/250/250/25
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mg
ThirstGeneral disorders1/266/2514/2515/25
PollakiuriaRenal and urinary disorders0/268/255/2512/25
Blood Alkaline Phosphatase IncreasedInvestigations1/266/253/252/25
InsomniaPsychiatric disorders1/261/256/256/25
ConstipationGastrointestinal disorders2/261/255/251/25
DiarrhoeaGastrointestinal disorders2/265/252/250/25
Blood Uric Acid IncreasedInvestigations1/263/254/255/25
Blood Bilirubin IncreasedInvestigations5/261/251/253/25
Blood Osmolarity IncreasedInvestigations1/260/250/254/25
Blood Urea IncreasedInvestigations4/264/254/253/25

Baseline characteristics

2 subjects (1 of placebo and 1 of OPC-41061 30 mg) were excluded by GCP deviation. 1 subject (OPC-41061 7.5 mg) was excluded by receiving a dose 7 times higher than specified daily dose.

Age, Continuous
Age, Continuous(years)PlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Mean63.5 ± 10.164.5 ± 9.464.8 ± 9.762.8 ± 10.463.9 ± 9.8
Age, Categorical
Age, Categorical(Participants)PlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
<=18 years00000
Between 18 and 65 years1311111348
>=65 years1314141253
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Female9741030
Male1718211571
Region of Enrollment
Region of Enrollment(participants)PlaceboOPC-41061 7.5 mgOPC-41061 15 mgOPC-41061 30 mgTotal
Japan26252525101
08

Study locations

7 sites
  • Chubu region, Japan
  • Chugoku region, Japan
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyusyu region, Japan
  • Tohoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2007
First posted
May 28, 2007
Start
Jun 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Mar 14, 2014
Last update
Mar 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00479336
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Jun 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Mar 14, 2014
Last update
Mar 14, 2014

Study contacts

Katsuhisa Saito
study director · Division of New Product Evalution and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion